Determinants and consequences of insulin initiation for type 2 diabetes in France: Analysis of the National Health and Wellness Survey

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 1007-1023

  Reach, Gérard ^a   Pautremat, Véronique Le ^b   Gupta, Shaloo ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b KANTAR HEALTH   (United States)

Author keywords

Adherence; Clinical inertia; Early insulin initiation; Psychological insulin resistance; Quality of life; Type 2 diabetes

Indexed keywords

INSULIN;

ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIABETOLOGIST; ENDOCRINOLOGIST; FEMALE; FOOT ULCER; FRANCE; GENERAL PRACTITIONER; HUMAN; INCOME; INSULIN TREATMENT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICATION COMPLIANCE; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; QUALITY OF LIFE; SMOKING; TRANSIENT ISCHEMIC ATTACK;

EID: 84886871226     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S51299     Document Type: Article

References (48)

1. Hu FB. Globalization of diabetes. The role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249-1257.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
4. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-559.
5. Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J. 2009;102:67-76.
6. Turner RC, Holman RR. Insulin rather than glucose homeostasis in the pathophysiology of diabetes. Lancet. 1976;1:1272-1274.
7. Le Roith D, Fonseca V, Vinik A. Metabolic memory in diabetes - focus on insulin. Diabetes Metab Res Rev. 2005;21:85-90.
8. Leslie CA, Satin-Rapaport W, Matheson D, et al. Psychological insulin resistance: a missed diagnosis. Diabetes Spectr. 1994;7:52-57.
9. Phillips LS, Branch WT Jr, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
10. Balkau B, Bouée S, Avignon A et al. Type 2 diabetes treatment intensification in general practice in France in 2008-2009: The DIAttitude study. Diabetes Metab. 2012;38: S29-S35.
11. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213-217.
12. El-kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS. Diabetes in urban African-Americans. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999;22:1617-1620.
13. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418-e424.
14. Shah BR, Hux JE, Laupacis A, Zinman B, Van Walraven C. Clinical inertia in response to inadequate glycemic control do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-606.
15. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000;93:369-374.
16. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
17. Peyrot M, Rubin RR, Khuntic K, et al. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4 Suppl 1:11-18.
18. Phillips P. Type 2 diabetes - failure, blame and guilt in the adoption of insulin therapy. Rev Diabetic Stud. 2005;2:35-39.
19. Woudenberg YJ, Lucas C, Latour C, Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796-802.
20. Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin-based therapy. Am J Manag Care. 2012;18(3):S55-61.
21. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;9999:9999.
22. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33:240-245.
23. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588-594.
24. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to Score Version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI: Quality Metric; 2002.
25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
26. Desai M, Clark A. Autoimmune diabetes in adults: lessons from the UKPDS. Diabet Med. 2008;Suppl 2:30-34.
27. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care. 2007;19:134-140.
28. Jotkowitz AB, Rabinowitz G, Raskin Segal A, Weitzman R, Epstein L, Porath A. Do patients with diabetes and low socioeconomic status receive less care and have worse outcomes? A national study. Am J Med. 2006;119:665-669.
29. Duru OK, Bilik D, McEwen LN, et al. Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study. J Gen Intern Med. 2011;26:505-511.
30. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a Diabetes Disease Management Program. J Manag Care Pharm. 2006;12:466-471.
31. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14:71-75.
32. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 2005;28:595-599.
33. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-245.
34. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437-443.
35. Lee R, Taira DA. Adherence to oral hypoglycemic agents in Hawaii. Prev Chronic Dis. 2005;2:A09.
36. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26:231-238.
37. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED Study 2007, a French population-based study. PLoS One. 2012;7:e32412.
38. Ahmed AT, Karter AJ, Liu J. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours. Diabet Med. 2006;23:795-802.
39. Reach G. Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients. Patient Prefer Adherence. 2011;5:523-531.
40. Jiménez-García R, Esteban-Hernández J, Hernández-Barrera V, et al. Clustering of unhealthy lifestyle behaviors is associated with nonadherence to clinical preventive recommendations among adults with diabetes. J Diabetes Complications. 2011;25:107-113.
41. Chiu CJ, Wray LA. Factors predicting glycemic control in middle-aged and older adults with type 2 diabetes. Prev Chronic Dis. 2010;7:A08.
42. Toljamo M, Hentinen M. Adherence to self-care and glycaemic control among people with insulin-dependent diabetes mellitus. J Adv Nurs. 2001;34:780-786.
43. Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care. 2000;23: 477-483.
44. Grégoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55:728-735.
45. Babiker MA. Compliance with penicillin prophylaxis by children with impaired splenic function. Trop Geogr Med. 1986;38:119-122.
46. Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol. 2006;17:183-184.
47. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications. 2007;21:220-226.
48. ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.